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Abstract 
 
The genome-wide accumulation of DNA replication errors known as microsatellite instability 
(MSI) is the hallmark lesion of DNA mismatch repair (MMR) deficient cancers. Although 
testing for MSI is widely used to guide clinical management, the contribution of MSI at distinct 
genic loci to the phenotype remains largely unexplored. Here we report that a mononucleotide 
(T/U)16 tract located in the 3’ untranslated region (3’UTR) of the Ewing sarcoma breakpoint 
region 1 (EWSR1) gene is a novel MSI target locus that shows perfect sensitivity and 
specificity in detecting mismatch-repair deficient cancers in two independent populations. We 
further found a striking re-localization of the EWSR1 protein from nucleus to cytoplasm in 
MMR-deficient cancers, and that the non-protein coding MSI target locus itself has a 
modulatory effect on EWSR1 gene expression through alternative 3’ end processing of the 
EWSR1 gene. Our results point to a MSI target gene-specific effect in MMR-deficient 
cancers.  
 
Précis 
This study identifies a novel genetic locus that is fully informative and accurate in detecting 
mismatch-repair deficient cancers, with major implications for routine daily practice in the 
clinic. 
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Introduction 
With an estimated population incidence of about 1 in 370, Lynch syndrome (LS, formerly 
known as hereditary non-polyposis colorectal cancer, HNPCC) represents the most common, 
autosomal dominantly inherited cancer predisposition world-wide(1), caused by germline 
mutations in DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2). Mutation 
carriers are at an increased risk to develop colorectal cancer (CRC) as well as a distinct 
spectrum of extracolonic cancers (predominantly of the endometrium, ovaries and stomach) 
at a young age(2). 
At the cellular level, biallelic inactivation of the MMR system leads to genome-wide 
accumulation of DNA replication errors at specific repetitive nucleotide sequences, a 
condition termed microsatellite instability (MSI). MSI is the hallmark lesion of MMR deficient 
cancers(3), but is also observed in 10 to 20% of the sporadic colorectal, gastric and 
endometrial cancers. The tumour’s MSI status is increasingly used to guide clinical 
management(3, 4), because genome-wide gene expression data from (sporadic) 
microsatellite stable (MSS) and unstable (MSI) CRCs demonstrated that tumor development 
in MMR-deficient cancers follows distinct pathogenetic paths(5). 
A large number of distinct genic loci affected by MSI have been described, consisting mainly 
of mono- and dinucleotide repeats within the 5’UTR (e.g. NR-27), introns (BAT-26) and the 
3’UTR (CAT25) of specific genes(6). The functional significance of MSI at these non-coding 
repeat loci and how they may contribute to the pathogenic process is, however, largely 
unknown(7). Here we report a novel target gene locus, EWS16T, consisting of a 
monomorphic polythymine (16T) tract within the 3UTR of the Ewing sarcoma gene (EWSR1). 
We assessed this locus in two independent populations and found that EWS16T 
discriminates MMR-deficient from MMR-proficient cancers, be they sporadic or hereditary, 
with high sensitivity and specificity. Despite its location in a non-coding region of the EWSR1 
gene, EWS16T contractions are associated with changes in EWSR1 expression and 
subcellular localization. Our findings thus directly implicate the RNA-/DNA-binding Ewing 
sarcoma protein, better known for its fused variants in Ewing sarcoma, in MSI-associated 
colorectal tumorigenesis. 
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Material and Methods 
DNA and RNA Isolation 
To isolate genomic DNA and total RNA from cell lines and fresh/frozen tumour tissue samples 
Qiagen QIAamp DNA/RNA Mini Kit (Qiagen, Hombrechtikon, Switzerland) and for formalin 
fixed paraffin embedded (FFPE) tumour samples RecoverAllTM Total Nucleic Acid Isolation Kit 
(Ambion, Invitrogen, Carlsbad, CA, USA) were used according to the manufacturers' 
guidelines. 
Analysis of Microsatellite Instability (MSI)  
Microsatellite instability was assessed on two independent cohorts of patients encompassing 
85 Lynch syndrome related cancers (78 CRCs and 7 endometrial carcinomas), 113 sporadic 
CRCs, including 14 cases with MLH1 promoter hypermethylation and 12 MMR-proficient, 
MSI-low cancers, and a Finnish cohort including 8 Lynch syndrome gastric related cancers, 
50 sporadic CRCs and 64 sporadic gastric cancers, all of which were compared to matched 
tumor free mucosa. Based on the recommendations of the National Cancer Institute 
workshop on MSI, a panel of microsatellite loci (BAT25, BAT26, D2S123, D5S346, D17S250) 
and two additional microsatellite markers (BAT40, MYCL1) were used to determine MSI 
status(8). The 3’UTR poly T(16) tract (EWS16T) of the EWSR1 gene (Ewing sarcoma 
breakpoint region 1; RefSeq: NM_005243) was amplified by PCR with the following primers: 
5'- AATGTTCATGGTTGTGATGT-3' (forward FAM-labelled) and 5'-
GAAGGATGACTCTTTATAA-3' (reverse). PCR products were analysed on an ABI 310 
Genetic Analyzer with GeneScan Analysis V 3.1 (PE Applied Biosystems, Foster City, CA) 
and Genotyper 2.0 (PE Applied Biosystems, Foster City, CA) software. Fragment analysis of 
PCR products allowed determination of novel alleles (expansions or contractions) within the 
repetitive tract of a given marker. The observed expansions or contractions in EWS16T were 
verified using a second set of primers covering the locus (Forward primer: 5’-
GCATGCTCAGTATCATTGTGG-3’; Reverse primer: 5’-AGGCCGAGAAGGATGACTCT-3’) 
for sequencing analysis of selected samples. Sequencing reactions using the Big Dye 
terminator chemistry (Applied Biosystems, Foster City, CA) were performed according to the 
manufacturer’s protocol. 
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Relative expression of EWSR1 by qPCR 
EWSR1 mRNA expression on fresh frozen tissues (8 Lynch syndrome related CRCs and 5 
sporadic CRCs both matched with their tumour free mucosa) was assessed using the 
TaqMan® Probe-Based Gene Expression Analysis (Applied Biosystems, Foster City, CA), 
and the EWSR1 probe Hs01580532_g1 (Applied Biosystems, Foster City, CA). The 
measurements were normalized using the HPRT1 probes Hs01003270_g1 (Applied 
Biosystems, Foster City, CA)(9, 10), and the fold-changes in gene expression were calculated 
using the standard Ct method(11). All retrotranscriptase reactions, including no-template 
controls, were run on an Applied Biosystem 7900HT thermocycler. Each sample was tested 
in triplicate unless specified otherwise. 
 
Immunohistochemistry 
Several cohorts of patients were studied by immunohistochemical analysis of EWS. Briefly, 
the tissue samples of the following cohorts of patients were analysed: 37 colon adenomas (9 
of which Lynch syndrome related), 19 CRCs (10 of which Lynch syndrome related) and a 
tissue microarray(12). Patient data including complete follow-up were obtained by 
retrospective analysis of medical records, regional tumour registries and/or treating 
physicians. Tissue samples were obtained by surgical or endoscopic excision. Tissue 
sections of 4 μm sections of paraffin embedded tissue were immunostained for primary 
antibody against EWS (Abcam clone 84389 dilution 1:800). Staining was carried out as 
previously described(13). Immunoreactivity was scored semi-quantitatively by evaluating the 
number of positive tumour cells over the total number of tumour cells. Nuclear 
immunoreactivity scores were assigned using 5% intervals and ranged from 0% to 100%. 
Regarding cytoplasmic expression, the staining intensity was scored as described by Allred et 
al.(14). All samples were examined independently by three different pathologists (S.P., F.T. 
and L.T.), blinded to clinicopathological and molecular genetic information.  
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Cell lines 
Human cell lines included in this study were purchased from American Type Culture 
Collection (ATCC, Rockville, MD) and authenticated by ATCC by short tandem repeat (STR) 
profiling and used for functional studies within 6 months after thaw from liquid nitrogen tank. 
All cell lines were maintained at 37°C with 5% CO2. 
Five colorectal cancer cell lines were used for this study: three mismatch repair (MMR) 
deficient cell lines (HCT116, LoVo, HCT15) and two MMR proficient ones (SW480 and 
HT29). HCT116 and HCT15 cells were cultured in RPMI 1640 (Invitrogen Basel, Switzerland) 
supplemented with 10% fetal bovine serum (FBS), 1% Kanamycin sulphate, 1% GlutaMAX-I, 
1% Sodium Pyruvate, 1% non Essential Amino Acids (NEAA), 1% HEPES (all from Invitrogen 
Basel, Switzerland) and 0.1% 2-mercapto-ethanol (Sigma-Aldrich Basel, Switzerland). LoVo 
cells were cultured in Ham’s F12 media supplemented with 10% FBS. HT29 cells were grown 
in McCoy's 5A Medium (Invitrogen Basel, Switzerland) with 10% FBS, Kanamycin sulphate 
and GlutaMAX-I (all from Invitrogen Basel, Switzerland). SW480 cells were cultured in L-15 
Medium (Sigma-Aldrich Basel, Switzerland) with 10% FBS, 1% GlutaMAX-I and 1% 
Kanamycin sulphate (all from Invitrogen Basel, Switzerland).  
HeLa cells at earlier passages were cultured in DMEM with GlutaMAX (Invitrogen) 
supplemented with 10% FBS.  
 
Plasmids and antibodies  
Synthetic poly(A) site of Renilla luciferase gene in dual luciferase psiCHECK-2 vector was 
mutated using primers psi-ck2polyAmutF: 5’-
GCGGCCGCTGGCCGCAGCTAAATATCTTTATTTTCA-3’ and psi-ck2polyAmutR: 5’-
TGAAAATAAAGATATTTAGCTGCGGCCAGCGGCCGC-3’ using QuikChange™ Site-
Directed Mutagenesis Kit as per manufacturer’s instruction to generate psiCHECK-2-
Synthetic polyA mutant (psiCHECK-2-SPAm). EWSR1 3’ UTR was PCR amplified from 
HEK293 genomic DNA using primers EWSR1_xhoIF: 5’-
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CCGACTCGAGCGGCCCTACTAGATGCAGAG-3’ and EWSR1_notIR: 5’-
ATAAGAATGCGGCCGCGAACCAACCGTTTACCTGGA-3’. The PCR amplicons were cloned 
into pGEM-T Easy and subsequently subcloned into psiCHECK-2-SPAm using XhoI and NotI 
restriction sites to generate EWSR1-wt-3’UTR/psiCHECK-2-SPAm reporter. Mutant 
constructs with U deletions (EWSR1-2/3/4/5/6 del-3’UTR/psiCHECK-2-SPAm) and insertions 
(EWSR1-2/4/ins-3’UTR/psiCHECK-2-SPAm) were introduced using standard overlap 
extension PCRs.  
Antibodies for Western blots against NF90, SFPQ and HuR were obtained from Santacruz 
Biotech and Antibody against EWSR1 for Western blots and Immunoprecipitation were 
obtained from Abcam.    
 
In vitro transcription 
In vitro transcription for pull down assay using S1 aptamer was performed using T7 
RiboMAX™ Express Large Scale RNA Production System (Promega) as per manufacturer’s 
instructions. Region flanking the wt- and deleted poly T/U tracks in the 3’UTR of EWSR1 
constructs was amplified using primers T7_EWSR1_IVT_Cf: 5’-GCTTCTAATACGACTCACT 
ATAGGGAGAAATGGGAACCCCTTGTGAG-3’ and EWSR1_IVT_Cr: 5’-GAACAGAGGCCGA 
GAAGGAT-3’ to introduce T7 promoter sequences at the 5’ end of the amplicons. S1 aptamer 
sequence was introduced at the 3’ end using another round of PCR using 
T7_EWSR1_IVT_Cf: 5’-GCTTCTAATACGACTCACTATAGGGAGAAATGGGAACCCCTTGT 
GAG-3’ and EWSR1_S1apt_IVT_Cr: 5’-CATGGCCCGGCCCGCGACTATCTTACGCACTTG 
CATGATTC TGGTCGGTCCCATGGATCCGAACAGAGGCCGAGAAGGAT-3’.  
 
Protein Pull-Down Assay 
For each sample, 100ul of the MyOne Streptavidin Dynal beads (Invitrogen) was washed 
twice with one bead volume of solution A (DEPC-treated 0.1 M NaOH, DEPC-treated 0.05 M 
NaCl) and once with one bead volume of Solution B (DEPC-treated 0.1 M NaCl) and once 
with RNA binding buffer. The beads were resuspended in one bead volume of RNA binding 
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buffer (100mM NaCl, 50mM Hepes 7.5, 0.5% NP-40 and 10mM MgCl2) with 100ug of in vitro 
transcribed RNA with S1 aptamer sequence and incubated at 10°C for 40 minutes in a 
thermomixer with intermittent shaking. The beads were washed twice with one volume of 
RNA wash buffer prior to incubation with the lysate. HEK293 cell pellet from 15cm2 dish was 
lysed in 3ml native lysis buffer (25mM Hepes-KOH pH 7.5, 100mM KCl, 0.5% NP-40, 5mM 
MgCl2, 0.5mM DTT , protease inhibitor cocktail, 1mM NaF, 1 mM Na4VO4 and 300U of 
RNasin) for 15 minutes on ice. The lysate was subsequently gently sonicated and centrifuged 
to remove any cell debris. 200ug of E. coli tRNA was additional added to prevent non-specific 
binding of proteins to the beads. 1 ml of the lysate was added to the beads coupled to S1 
aptamer RNA and also to the beads alone for no RNA control. The mixture was incubated at 
4°C on rotation wheel. After 1 hour of incubation, the beads were washed thrice with native 
lysis buffer. The bound proteins were eluted with 100ul native lysis buffer supplemented with 
25mM Biotin for 30-45 minutes at 10°C on a thermomixer with intermittent shaking. 900ul of 
100% ethanol was added to the eluate and incubated at -80°C for 2 hours followed by 
centrifugation to precipitate the eluted proteins. The pellet was air dried and dissolved in 35ul 
of (SDS loading dye). Prior to loading on the Nuvex gradient gels, the samples were heated 
at 90°C for 5 minutes. After SDS-PAGE electrophoresis, the gel was stained with colloidal 
blue and bands of interest were excised and sent for mass spectrophotometry. 
Poly(A) site selection assay 
HeLa cells were transfected with psiCHECK-2-SPAm constructs for 24 hours. Total RNA was 
isolated from the HeLa cells using TriReagent (Sigma) followed by DNAse I (Promega) 
treatment according to the manufacturer’s protocol. Reverse transcription was done with oligo 
d(T)18 primers for 1 hour. For poly(A) site selection assay, multiplexed polymerase chain 
(PCR) reaction was set up using a single forward primer specific to the psiCHECK-2 vector 
(psiCHECK-2-SeqFor: 5’-ATGAAATGGGTAAGTACA-3’) and two 4 nucleotide terminally 
anchored oligo d(T)16 reverse primers specific to the two isoform variants of EWSR1 
(EWSpolyAproxR: 5’-TTTTTTTTTTTTTTTTACCA-3’ and EWSpolyAdistR: 5’-
TTTTTTTTTTTTTTTTGACT-3’ respectively) to detect only the isoforms generated specifically 
from the psiCHECK-2-SPAm constructs. PCR was run for 28 cycles and the products were 
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separated on a 2 % Agarose gel. The bands were quantified using the ImageJ software 
(http://rsbweb.nih.gov/ij/).     
 
Luciferase assays 
HeLa cells were seeded in a 48 well plate one day prior to transfection. 0.2ug of plasmids 
(psiCHECK-2-SPAm constructs) were transfected with Lipofectamine 2000 (Invitrogen) for 24 
hours. Luciferase assays were done on the transfected cells using The Dual-Luciferase® 
Reporter Assay System (Promega). Both transfections and luciferase assays were done 
according to the manufacturer’s protocol.  
siRNA transfections 
Control-siRNAs and siRNAs against hnRNPC, HuR, NF90 and SFPQ and were obtained from 
Santa Cruz Biotechnology. HeLa cells were reverse transfected with siRNA oligos using 
RNAiMAX (Invitrogen). After 48 hours the cells were transfected with EWSR1-wt-3’UTR- and 
EWSR1-6del-3’UTR-psiCHECK-2-SPAm-constructs for another 24 hours. The cells were 
subsequently harvested and split into two aliquots. One aliquot was used to assess the 
knockdown efficiency of siRNA using Western blot, while the other was used for RNA 
isolation and subsequent poly(A) site selection assay.  
Statistical Analyses 
For statistical analysis, the chi-square test (2 test) and Fisher's exact test for nonparametric 
variables and Student’s t-test for parametric variables were used, with all probabilities 
reported as 2-tailed, considering a P<0.05 to be statistically significant. Calculations were 
performed using the software program SPSS 17.0 (IBM Corporation, Somers, NY 10589). 
Ethical approval 
The study is part of the so-called “Basler Studie über familiaere Tumorkrankheiten”, Ref.Nr. 
EK258/05 and has been approved by the “Ethikkommission beider Basel”. Furthermore, 
written informed consent was obtained from all Lynch syndrome patients as well as from the 
sporadic patients. 
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Results  
The initial investigation of a primary (vimentin- and CD99-positive) extra-osseous Ewing 
sarcoma (ES) from a MSH6 mutation carrier (c.3696dupT) previously affected by colon 
cancer revealed that the tumor displayed the typical hallmarks of LS, i.e. MSI at 
mononucleotide markers and specific loss of MSH6 expression (Supplementary Fig. S1), but 
none of the molecular features commonly associated with ES, i.e. chromosomal 
translocations involving the EWSR1 gene locus on 22q12 (Supplementary Fig. S2). 
Reasoning that the EWSR1 gene is likely involved in the development of this Ewing sarcoma 
tumour and in view of the tumour’s MSI-high phenotype we focused on a mononucleotide 
tract in the 3’ UTR of the EWSR1 gene consisting of 16 thymines (EWS16T; c.*318_*333) 
which we thought would be a likely MSI target. Strikingly, both of the patient’s tumors, the 
Ewing sarcoma as well as the colon cancer, were found to carry somatic 
contractions/deletions of 4 and 5 thymines, respectively. This prompted us to assess the 
prevalence of somatic alterations at EWS16T in MMR-deficient cancers in general. In contrast 
to Wheeler et al.(15), who reported a deletion variant (c.*331_*333delTTT; dbSNP: 
rs76631619) in James D. Watson’s genome, we found the EWS16T locus to be quasi-
monomorphic in 370 (99.7%) out of 371 constitutional (i.e. tumor-free) DNA samples tested.  
EWS16T: a novel target gene locus in Lynch Syndrome-related cancers. 
To determine whether EWS16T is indeed a novel target gene locus in Lynch syndrome (LS) 
we analysed 85 matched tumor-free tissue and cancer samples (78 colorectal (CRC) and 7 
endometrial) from 78 Swiss LS patients with confirmed MMR germline mutation (58 MLH1, 20 
MSH2). We further investigated 14 sporadic MMR-deficient CRCs with MLH1 promoter 
hypermethylation as well as 86 sporadic MMR-proficient CRCs. Assessment of EWS16T tract 
length by capillary electrophoresis of fluorescently labelled PCR products revealed that all 
MMR-deficient cancers but none of the MMR-proficient ones displayed novel alleles, i.e. 
contractions or expansions at the EWS16T tract (Fig. 1). These findings were further 
confirmed independently in a Finnish cohort of 122 patients. In this patient cohort as well all of 
the 29 MMR-deficient (12 CRC, 17 gastric cancers) but none of the 93 MMR-proficient (38 
CRC and 55 gastric) cancers showed EWS16T tract instability. The majority (72.7%) of 
somatic alterations consisted of contractions/deletions of 4 or more base pairs 
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(Supplementary Fig. S3). Consistently, we found that all MMR-deficient cell lines investigated 
(LoVo, HCT15, HCT116) carried solely mutated EWS16T alleles (contractions) without 
evidence for a wild-type tract allele. In contrast, MMR-proficient cell lines (HT29, SW480) as 
well as 37 microsatellite-stable colon adenomas and 12 MMR-proficient, MSI-low CRCs from 
Swiss patients had a stable EWS16T locus (Table 1). Thus, the EWS16T tract represents a 
novel, quasi-monomorphic MSI target locus identifying hereditary and sporadic MMR-deficient 
cancers with 100% sensitivity (95% CI 97-100) and specificity (95% CI 98-100). 
 
EWSR1 poly(T/U) tract deletions promote distal poly(A) site usage. 
Fusion of EWSR1 with ETS family transcription factors as a result of chromosomal 
translocations has long been implicated in the development of Ewing sarcoma(16). It is still 
debated to what extent tumorigenesis is the consequence of the fusion protein as opposed to 
the loss of function of the normal EWSR1 protein. Because somatic EWS16T tract alterations 
were exclusively present in MMR-deficient cancers, whether hereditary or sporadic, and 
occurred in all types of cancer investigated (colorectal, gastric and endometrial) we wondered 
about their possible functional role(s) in MMR-related carcinogenesis. The poly(T/U) tract 
deletions occur in a region which encodes the 3’UTR of EWSR1 and therefore do not alter the 
coding sequence of the EWSR1 gene. Nonetheless, 3’UTRs contain sequence elements that 
are important for the post-transcriptional regulation of protein levels. Furthermore, it has been 
recently demonstrated that changes in 3’UTR length through alternative polyadenylation 
activates oncogenes(17). We thus set out to characterize the effect of EWS16T tract 
deletions on EWSR1 expression levels. A recently generated catalogue of polyadenylation 
sites identified through 3’ end sequencing from human embryonic kidney (HEK) 293 cells(18) 
shows that EWSR1 undergoes alternative polyadenylation, generating two transcript forms 
that differ in the length of their 3’UTRs (Supplementary Fig. S4). The ESW16T tract deletions 
occur very close to the distal poly(A) signal and may thus result in changes in 3’ end 
processing factor assembly, thereby altering the poly(A) site selection. To investigate this 
possibility, we cloned the 3’UTR of EWSR1 downstream of the Renilla luciferase-coding 
region in a psiCHECK-2 mutant vector in which the synthetic poly(A) site was mutated 
(psiCHECK-2-SPAm). This construct thus allowed only the usage of the poly(A) signal from 
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the cloned 3’UTR of EWSR1. We then generated variant constructs containing poly(T/U) 
tracts of variable lengths through deletion mutation. With primers that simultaneously detect 
both the short and the long 3’UTR isoforms in a multiplexed semi-quantitative PCR, we found 
that deletions in the ESW16T tract promoted the usage of the distal poly(A) site (Figure 2a-b). 
We further investigated the MMR-proficient and MMR-deficient colon cancer cell lines and 
found that, consistent with our findings in the heterologous system, MMR deficiency is 
associated with higher expression of the longer EWSR1 isoform (Figure 2c). These results 
indicate that the EWS16T tract deletions indeed alter poly(A) site selection.  
 
SFPQ but not HuR or NF90 mediates distal poly(A) site usage in EWSR1 pre-mRNAs 
with EWS16T tract deletions. 
To determine the factors involved in EWSR1 poly(A) site selection, we used S1 aptamer-
tagged, in vitro transcribed wildtype 3’UTR and a 3’UTR variants with 6U deletions in the 
EWS16T region to pull down the proteins that associated with these RNAs (Supplementary 
Fig. S5). In three independent experiments we reproducibly identified a set of A/U-rich 
element binding proteins that associate with these constructs (Figure 3A and 3B). 
Interestingly, we found that nuclear factor 45/90/110 (NF45/90/110), heterogeneous nuclear 
ribonucleoprotein C (hnRNPC) and human antigen R (HuR) associate with the wildtype but 
not with the mutant 3’UTR. NF45 and NF90 have been previously shown to be part of a 
heterodimeric complex, nuclear factor of activated T-cells (NFAT), which is required for T-cell 
expression of interleukin 2, with NF110 being the larger isoform of NF90. NF90 has been 
shown to regulate mRNA stability and redistribution of nuclear mRNAs in the cytoplasm(19). 
Conversely, the EWS16T mutant preferentially associated with the SFPQ/NONO 
heterodimer, which is an essential pre-mRNA splicing factor that couples splicing with 
polyadenlyation as a component of a small nuclear ribonucleoprotein (snRNP)-free complex 
with SNRPA/U1A(20). Strikingly, NONO has recently been implicated in the cellular response 
to DNA double-strand breaks [PMID: 22941645]. 
To determine which of the RNA binding proteins (RBP) identified above influenced the poly(A) 
site selection, we knocked down their expression individually with siRNAs (Figure 4a) and 
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assessed the poly(A) site usage in reporter constructs that had either the wildtype or the 
mutant EWS16T tract (6U deletions) cloned downstream of luciferase. None of the siRNAs 
influenced the poly(A) site usage in the wildtype constructs in which only the shorter isoform 
was expressed (Figure 4b). When the 6U deletion construct was used, however, the 
knockdown of SFPQ and hnRNPC strongly influenced poly(A) site selection. Specifically, 
knockdown of SFPQ promoted proximal site usage, while the knockdown of hnRNPC led to 
increased expression of the longer 3’UTR isoform (Figure 4c). This result was consistent with 
the observed binding pattern of the RBPs. hnRNPC binding was most prominent immediately 
downstream of the proximal poly(A) site (our unpublished PAR-CLIP data on hnRNPC), while 
SFPQ most likely bound to the truncated U-tract immediately upstream of the distal poly(A) 
site, as inferred from the pull down experiments (Figure 3a). Interestingly, knockdown of 
SFPQ did not affect poly(A) site selection in wildtype constructs, consistent with our earlier 
findings that SFPQ specifically associated with the construct carrying the 6U deletion. Thus, 
our results indicate that hnRNPC and SFPQ have antagonistic activity on the processing of 
mutant EWSR1 pre-mRNA with hnRNPC promoting the generation of the shorter and SFPQ 
of the longer 3’UTR isoform.  
 
Distal poly(A) site usage is associated with decreased EWSR1 expression. 
To determine if the choice in polyadenylation site may influence EWSR1 expression, we 
performed luciferase assays on the constructs that carried the wildtype or various EWS16T 
deletion variants. The results shown in Supplementary Fig. 6 indicate a significant 
downregulation (up to 30%) of protein levels associated with EWS16T tract deletions. We 
attempted to corroborate our observations in vivo, assessing EWSR1 mRNA expression in a 
set of 8 LS-related MMR-deficient and 5 sporadic MMR-proficient CRCs relative to matched, 
tumor-free mucosa by qPCR. Four (50%) out of the 8 LS, but only 1 (20%) out of the 5 
sporadic CRC showed significantly (>1.2 fold) increased expression of the longer 3’UTR 
isoform (Figure 5A). The total EWSR1 mRNA levels, however, were significantly reduced 
(>1.2 fold) in both LS-related and sporadic CRC tissues compared to the matched, tumor-free 
mucosa (Figure 5B), pointing to additional mechanisms that regulate EWSR1 expression in 
on March 12, 2014. © 2013 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 24, 2013; DOI: 10.1158/0008-5472.CAN-13-2100 
 14
sporadic CRCs. Alternatively, qPCR interpretation may have been compromised by the 
presence of non-cancer cells, especially in MMR-deficient cancer specimens. 
To determine the consequences of altered EWSR1 mRNA expression in vivo, we performed 
immunohistochemical analysis (IHC) of 10 LS-related, MMR-deficient and 9 sporadic, MMR-
proficient CRCs. Consistent with the data obtained at the mRNA level, the cancers displayed 
on average an approx. 30% reduction in EWS expression when compared to matched, tumor-
free mucosa. Surprisingly however, MMR-deficient and -proficient cancers significantly 
differed with regard to the subcellular localization of EWS (P<0.001).  Tumor-free colon 
mucosa and adenomas from LS and sporadic CRC patients as well as sporadic 
adenocarcinomas showed exclusively nuclear expression (Fig. 6). In contrast, LS-related 
CRCs displayed diffuse cytoplasmic EWS expression (Fig. 6). These results were 
subsequently confirmed by IHC analysis of a tissue microarray (TMA) containing 64 sporadic 
and 94 LS-related CRCs: we observed an approx. 30% reduction in EWS expression in both 
groups, but only the LS-related cancers showed diffuse cytoplasmic staining for EWS (61% 
vs 3% of the sporadic cancers, p<0.001). Thus, MMR-deficient CRCs, all carrying somatic 
EWS16T tract alterations, display a distinct subcellular EWS distribution pattern in vivo. 
Further studies, ideally performed on EWS16T-mutated CRC cell lines, are needed to assess 
if this is directly related to EWS16T tract alterations or, rather, an indirect consequence of 
MSI-associated genetic instability affecting regulators of EWSR1 protein localization such as 
the methyl-transferases like PRMT1, which is known to regulate the localization of EWS(21) 
by methylating Glycine/Arginine-rich motifs located in the arginine-glycine-glycine domains of 
EWS.  
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Discussion 
EWS16T, a polyT/U tract in the 3’UTR of the EWSR1 gene, represents a novel, quasi-
monomorphic MSI target gene locus that identifies both hereditary and sporadic MMR-
deficient colorectal cancers with perfect (100%) diagnostic sensitivity and specificity. Given 
this high diagnostic accuracy and quasi-monomorphic nature ascertained in more than 300 
cancers, EWS16T has the potential to substantially facilitate and improve the accuracy of MSI 
detection in routine daily practice and prospective studies are now needed to determine 
whether EWS16T alone could replace the set of multiple diagnostic markers currently 
employed for MSI testing. 
3 untranslated regions (3UTRs) play an essential role in regulating the stability, subcellular 
localization, and translation of corresponding mRNAs via sequence-specific interactions with 
trans-acting factors including small RNAs and proteins(22). Several 3UTR point mutations 
have been linked to the risk of developing cancer in humans(23-28). Recent reports have 
shown that contractions at 3UTR mononucleotide repeats can exert deleterious effects by 
destabilizing the respective mRNAs associated with them and thereby be of direct 
pathophysiological relevance(29, 30). Characterization of 3’UTR MSI target genes thus can 
provide important insights into the consequences of MMR for gene expression. Our 
investigations of the in vitro and in vivo effects of EWS16T alterations conclusively show that 
contractions at this locus indeed affect multiple regulatory mechanisms such alternative 
polyadenylation, mRNA / protein expression and possibly subcellular localization. Given that 
EWS is an RNA-/DNA-binding protein with many RNA/DNA targets, these alterations provide 
new leads into the mechanisms behind MSI-associated colorectal tumorigenesis.  
The physiological role of EWS is largely unknown but based on its domain structure the 
protein is thought to be involved in such diverse processes as gene expression, RNA 
processing / transport and cell signalling. Knockout of EWS in mice results in high postnatal 
lethality, defects in pre-B cell development, meiotic arrest/germ cell apoptosis, premature 
cellular senescence, and hypersensitivity to ionizing radiation (IR) (31). These observations 
suggest roles for EWS in homologous recombination, DNA damage response, and 
maintenance of genome integrity (32). Indeed, we recently found that EWSR1 binds RNAs 
that originate at intrinsically unstable genomic loci and its knockdown increases the frequency 
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of double-strand DNA breaks (Kishore et al., data not shown). 
With respect to tumorigenesis, genetic alterations in EWSR1 were first observed in Ewing 
sarcoma, the second most common malignant bone tumor in adolescents and young adults 
after osteosarcoma(16, 33, 34). In about 85% of cases, an EWSR1-FLI1 fusion protein is 
observed which has retained the N-terminal transcription activation domain but lost the RNA-
binding domains, which are replaced with the DNA binding domain of the fusion partner (35). 
The fusion protein is constitutively active and has been shown to alter the transcription of 
several downstream targets. Ewing Sarcoma is thus largely thought of as a gain of function 
phenotype. Loss of the EWSR1 function has been largely overlooked, in spite of the fact that 
the protein has a canonical RNA binding domain and has been shown to regulate several 
RNA processing events in the nucleus (36, 37). As a member of the TET (TLS/FUS, EWS, 
and TAF15) family of RNA- and DNA-binding proteins it has been involved in transcriptional 
regulation and RNA processing (38) (39) (40) (41, 42).  Consistent with this potential dual 
role, EWS has been shown to regulate cyclin D1 transcripts both transcriptionally and at the 
level of splicing, with the oncogenic fusion protein EWS-FLI1 promoting the expression of the 
oncogenic cyclin D1b splice variant in Ewing sarcoma cells (43). More recently, EWS has 
been shown to regulate alternative splicing (AS) of the p53 repressor MDM2 and to be part of 
the microprocessor complex that mediates the genesis of microRNAs (32, 42) (44).  
In summary, the EWS16T locus represents a novel, quasi-monomorphic MSI target locus to 
accurately identify both hereditary and sporadic MMR deficient cancers. Contractions therein 
affect EWSR1 at multiple levels including alternative polyadenylation, mRNA / protein 
expression and possibly subcellular localization. Our results thereby implicate the RNA-/DNA-
binding protein EWSR1, critical for the maintenance of genome integrity(45), in MSI-
associated colorectal tumorigenesis. 
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Tables 
Table1 
 
Samples analyzed n MSI status EWS16T tract status  
wildtype
 n (%) 
contraction  
n (%) 
expansion 
n (%) 
MMR deficient cancers 
• Colorectal 
• MLH1 deficient 
• MSH2 deficient 
• Gastric 
• MLH1 deficient 
• MSH2 deficient 
• Endometrial 
• MLH1 deficient 
• MSH2 deficient  
128 
104 
76 
28 
17 
16 
1 
7 
4 
3 
MSI-High 
 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
126 (98.4) 
102 (98.0) 
76 (100) 
26 (92.9) 
17 (100) 
16 (100) 
11 (100) 
7 (100) 
4 (100) 
3 (100) 
2 (1.6) 
2 (2.0) 
0 
2 (7.1) 
0 
0 
0 
0 
0 
0 
MMR proficient cancers 
• Colorectal 
• Colorectal 
• Gastric 
191 
124 
12 
55 
MSS/ MSI-
Low 
MSS 
MSI-Low 
MSS 
190 (100) 
124 (100) 
12 (100) 
55 (100) 
0 
0 
0 
0 
0 
0 
0 
0 
MMR proficient colon 
adenomas 
• Lynch syndrome-related 
• MLH1 deficient 
• MSH2 deficient 
• Sporadic 
37 
10 
8 
2 
27 
MSS 
 
37 (100) 
10 (100) 
8 (100) 
2 (100) 
27 (100) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
Table 1: EWS16T tract instability in 34 colon adenoma and 319 cancer samples. 
Microsatellite instability was determined according to Umar et al. (8). MMR: mismatch repair; 
MSI: microsatellite instability; MSS: microsatellite stable. 
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 FIGURE LEGENDS 
Figure 1: EWS16T tract instability in MMR deficient cancers as determined by capillary 
electrophoresis of fluorescently labeled PCR products. The dotted line corresponds to the 
wild-type allele (16T). MMR-proficient cancers (a) colorectal, (b) gastric; MMR-deficient 
cancers with expansion (c) or contraction of EWS16T (d-h): (c) colorectal (MSH2 germline 
mutation), (d) colorectal (MSH2), (e) colorectal (MLH1 promoter hypermethylation), and 
cancers with an MLH1 germline mutation (f-h): (f) colorectal, (g) gastric, (h) endometrial. 
Figure 2: Poly(A) site selection assay through multiplexed PCR. a) Schematic diagram of the 
multiplexed semi-quantitative protocol for poly(A) site selection assay. A single forward 
primer, which was either vector specific (for analyzing poly(A) usage of reporter constructs) or 
EWSR1 -3’UTR specific (for analyzing endogenous EWSR1 poly(A) usage), was used along 
with two terminally anchored reverse primers to yield amplicons representing both long and 
short variants of EWSR1 3’UTR in a single PCR reaction. b) Poly(A) site usage in EWSR1 
3’UTR constructs with variable poly(T/U) tracts lengths cloned in psiCHECK-2-SPAm vector 
along with the quantification of distal poly(A) site usage (percentages). c) Poly(A) site usage 
in endogenous EWSR1 gene across various MMR-deficient and -proficient cell lines. 
Figure 3: Identification of proteins associated with the 3’UTR of EWSR1 in a pull down assay. 
A) Colloidal blue stained SDS PAGE gel showing proteins specifically interacting with in vitro 
transcribed, S1 aptamer-tagged EWSR1-wt or -6del 3’UTR. “No RNA” refers to the control 
sample where beads were incubated with cellular lysate without a prior incubation with RNA, 
allowing detection of any proteins interacting non-specifically with the MyOne Streptavidin 
beads. Bands specifically present in either wt or 6del lanes were excised and submitted to 
protein identification by mass spectrometry. Identified proteins have been labeled next to the 
corresponding bands. B) Western blot confirming the results of mass spectrometry. Western 
blot with antibody raised against HuR (a), SFPQ (b) and NF90 (c) proteins. The membrane 
from (b) was used to reblot with anti-NF90 in (c). Asterix in (c) depicts the background signal 
from SFPQ in (b).    
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Figure 4: Knockdown of RNA binding proteins identified from pull down assays showing that 
SFPQ and hnRNPC specifically modulate poly(A) site usage in EWSR1 3’UTR reporter 
constructs. a) Western blot showing the knock down of the RNA-binding proteins after 72 
hours. Poly(A) site usage in b) EWSR1-wt-psiCHECK-2-SPAm and c) EWSR1-6del-
psiCHECK-2-SPAm reporter constructs upon knock down of RNA binding proteins. d) 
Quantification of the relative poly(A) site usage in c).   
Figure 5: Quantitative Real-Time PCR showing EWSR1 expression in tumor relative to 
matched normal tissue. A) Difference in poly(A) site usage in endogenous EWSR1 mRNA 
(distal/proximal) and B) difference in total EWSR1 mRNA levels. Samples showing more than 
1.2 fold difference are indicated with an asterix. 
Figure 6: Immunohistochemical staining of EWS. a) Normal colonic mucosa from sporadic 
CRC patient. b) Sporadic, MMR proficient colon adenoma with nuclear expression. c) 
Sporadic, MMR proficient colon adenocarcinoma with nuclear expression. d) Normal colonic 
mucosa from Lynch syndrome-related CRC patient. e) MMR deficient colon adenoma with 
nuclear expression. f) MMR deficient colon adenocarcinoma with nuclear and diffuse 
cytoplasmic expression.  
CRC, colorectal cancer. 
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